Merck & Co., Inc. $MRK Shares Sold by Commonwealth Retirement Investments LLC

Key Points

• Commonwealth Retirement Investments LLC reduced its Merck stake by 11.3% in the second quarter, selling 10,599 shares and retaining 83,307 shares valued at approximately $10.7 million. Institutional investors and hedge funds collectively own 76.07% of MRK.
• Merck reported quarterly revenue of $16.61 billion, above the $16.37 billion consensus estimate, while adjusted EPS of $(0.13) beat expectations by $0.13. The company also declared a quarterly dividend of $0.85, equivalent to a 2.3% annual yield.
• Insiders sold 228,238 shares worth nearly $30 million over the past 90 days, while analysts remain broadly positive with a “Moderate Buy” consensus and an average price target of $142.10. Shares opened at $149.25, near the company’s 52-week high of $153.50.

Commonwealth Retirement Investments LLC cut its holdings in Merck & Co., Inc. (NYSE:MRK - Free Report) by 11.3% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 83,307 shares of the company's stock after selling 10,599 shares during the quarter. Merck & Co., Inc. accounts for 2.9% of Commonwealth Retirement Investments LLC's portfolio, making the stock its 5th biggest holding. Commonwealth Retirement Investments LLC's holdings in Merck & Co., Inc. were worth $10,705,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of MRK. Kingdom Financial Group LLC. acquired a new stake in Merck & Co., Inc. in the fourth quarter valued at $25,000. Abound Financial LLC purchased a new stake in shares of Merck & Co., Inc. during the 4th quarter worth $26,000. Prosperity Bancshares Inc acquired a new position in shares of Merck & Co., Inc. during the 4th quarter worth $26,000. High Note Wealth LLC grew its stake in shares of Merck & Co., Inc. by 58.9% during the 4th quarter. High Note Wealth LLC now owns 294 shares of the company's stock worth $31,000 after purchasing an additional 109 shares during the period. Finally, IFC & Insurance Marketing Inc. purchased a new position in shares of Merck & Co., Inc. in the 4th quarter valued at about $31,000. Institutional investors and hedge funds own 76.07% of the company's stock.

Merck & Co., Inc. Trading Down 1.9%

NYSE:MRK opened at $149.25 on Friday. Merck & Co., Inc. has a 52-week low of $77.58 and a 52-week high of $153.50. The company has a quick ratio of 1.10, a current ratio of 1.32 and a debt-to-equity ratio of 1.22. The stock has a fifty day simple moving average of $127.43 and a 200-day simple moving average of $121.01. The company has a market capitalization of $368.23 billion, a PE ratio of 119.40, a price-to-earnings-growth ratio of 6.56 and a beta of 0.19.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.13. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The company had revenue of $16.61 billion for the quarter, compared to the consensus estimate of $16.37 billion. During the same quarter in the prior year, the firm earned $2.13 earnings per share. The company's revenue for the quarter was up 5.1% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. On average, equities research analysts expect that Merck & Co., Inc. will post 2.77 earnings per share for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 7th. Stockholders of record on Tuesday, September 15th will be given a $0.85 dividend. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.3%. Merck & Co., Inc.'s payout ratio is currently 272.00%.

Insiders Place Their Bets

In other Merck & Co., Inc. news, EVP Jennifer Zachary sold 80,315 shares of Merck & Co., Inc. stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $133.46, for a total value of $10,718,839.90. Following the completion of the sale, the executive vice president owned 45,509 shares in the company, valued at $6,073,631.14. The trade was a 63.83% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP David R. Maraldo sold 18,706 shares of the business's stock in a transaction that occurred on Wednesday, August 5th. The shares were sold at an average price of $128.72, for a total transaction of $2,407,836.32. Following the completion of the sale, the executive vice president owned 18,212 shares of the company's stock, valued at approximately $2,344,248.64. The trade was a 50.67% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 228,238 shares of company stock valued at $29,977,783. 0.17% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several research analysts have weighed in on MRK shares. JPMorgan Chase & Co. upped their target price on shares of Merck & Co., Inc. from $135.00 to $140.00 and gave the stock an "overweight" rating in a research report on Monday, July 13th. CICC Research assumed coverage on shares of Merck & Co., Inc. in a research report on Wednesday, June 24th. They set an "outperform" rating and a $138.00 price target for the company. Citigroup started coverage on shares of Merck & Co., Inc. in a research report on Wednesday, May 6th. They set a "neutral" rating and a $125.00 price target for the company. Daiwa Securities Group raised Merck & Co., Inc. from a "neutral" rating to an "outperform" rating and set a $143.00 price target on the stock in a research note on Wednesday, August 12th. Finally, Royal Bank Of Canada cut Merck & Co., Inc. from an "outperform" rating to a "sector perform" rating and upped their price target for the stock from $142.00 to $150.00 in a report on Thursday. Fifteen research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $142.10.

More Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck and Moderna reported that their individualized mRNA vaccine, used with Merck’s Keytruda, met the Phase 3 primary endpoint in high-risk melanoma. The combination improved recurrence-free survival and distant-metastasis-free survival compared with Keytruda alone, marking the first positive late-stage result for an mRNA cancer vaccine. The result could expand Merck’s oncology pipeline and help address the eventual loss of Keytruda exclusivity. Merck, Moderna say melanoma skin cancer vaccine meets goals in large trial
• Positive Sentiment: Morgan Stanley upgraded MRK to overweight and raised its price target to $179 from $116, while UBS lifted its target to $175 and BMO raised its target to $170, reflecting increased confidence in the cancer-vaccine opportunity and Merck’s broader growth prospects. Merck upgraded at Morgan Stanley after cancer trial win; RBC downgrades
• Neutral Sentiment: Analysts cautioned that the initial results are not a complete regulatory or commercial victory. Full data, regulatory approval expected no earlier than 2027, manufacturing execution and the therapy’s eventual pricing and market adoption remain key uncertainties. Moderna's Cancer Vaccine: Are Investors Putting The Cart Before The Horse?
• Negative Sentiment: RBC downgraded MRK to sector perform and set a $150 target, arguing that the roughly $150 valuation is unusually demanding for a company facing a major Keytruda loss of exclusivity in about two years. Jefferies also moved the stock to hold, creating a valuation overhang despite the trial success. Merck’s Cancer-Vaccine Trial Results Surpassed Expectations – So, Why Did RBC Downgrade MRK Stock?
• Negative Sentiment: Broader healthcare weakness and profit-taking after Merck’s sharp rally are adding pressure, while the stock’s elevated valuation leaves less room for disappointment. Sector Update: Healthcare Stocks Fall Thursday Afternoon

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source